of molecular and medical science
Jonathan Rothbard, PhD, is a scientist with over fifty years of experience spanning molecular chemistry, immunology, drug delivery, inflammation biology, and therapeutic innovation. His work has contributed foundational insights into MHC class I and II peptide interactions, T cell recognition, intracellular delivery systems, and neuroimmune pathways.
He has authored more than 160 peer-reviewed publications and is the inventor on 20 issued U.S. patents. Jonathan has founded and served as Chief Scientific Officer for four biotechnology companies — ImmuLogic, Amylin, CellGate, and Katexco/180 Life Sciences — with all four becoming public companies listed on NASDAQ. His early work contributed to the eventual $7B acquisition of Amylin by Bristol Myers Squibb.
Today, he brings this exceptional scientific depth to individuals and families facing complex medical decisions. When complicated diagnoses arise, Jonathan translates the underlying biology, clarifies options, evaluates evidence, and provides scientific guidance grounded in decades of discovery and therapeutic development.
Detailed explanation of therapeutic mechanisms, molecular targets, clinical evidence, and realistic outcomes.
Scientific assessment of investigational therapies, including mechanism plausibility, risks, and applicability to your case.
Participation in medical consultations by phone or video to ensure the right scientific questions are asked and answered.
Expert review of diagnostic reports, pathology, and proposed treatments, integrating decades of research and translational experience.